Novartis AG (New York Stock Exchange:NVS)
| Market Cap | 292.35B+19.1% |
| Revenue (ttm) | 55.63B+0.8% |
| Net Income | 12.76B-6.6% |
| EPS | 6.63-3.4% |
| Shares Out | 1.90B |
| PE Ratio | 23.38 |
| Forward PE | 15.70 |
| Dividend | $4.47(2.90%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 2,815,397 |
| Open | 153.95 |
| Previous Close | 151.12 |
| Day's Range | 152.78 - 154.31 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.42 |
| Analysts | Hold |
| Price Target | 146.00(-5.08%) |
| Earnings Date | Oct 27, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About NVS
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Analyst consensus
1 firm rating NVS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Oct 27, 2026Earnings report
Ask Barron about NVS
$NVS stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of NVS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Kevin HernHouse / R | Sale$15.00K – $50.00K | Aug 27, 2026 |
| Alan ArmstrongSenate / R | Purchase$1.00K – $15.00K | Mar 31, 2026 |
| Alan ArmstrongSenate / R | Purchase$15.00K – $50.00K | Mar 30, 2026 |
| Sheldon WhitehouseSenate / D | Sale$1.00K – $15.00K | Apr 9, 2024 |
| Sheldon WhitehouseSenate / D | Purchase$15.00K – $50.00K | Sep 20, 2023 |
| Kevin HernHouse / R | Sale$1.00K – $15.00K | Jan 31, 2023 |
| Kevin HernHouse / R | Sale$1.00K – $15.00K | Jan 30, 2023 |
| Alan LowenthalHouse | Sale$15.00K – $50.00K | Nov 23, 2020 |
Recently reported changes in NVS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NVS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NVS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NVS Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New NVS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NVS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NVS
| ETF | Est. Holding Size |
|---|---|
| DFIVDimensional - International Value ETF | $134.32M |
| DFAIDimensional - International Core Equity Market ETF | $118.89M |
| DFICDimensional - International Core Equity 2 ETF | $109.39M |
| AVDEAvantis International Equity ETF | $91.32M |
| DIHPDimensional International High Profitability ETF | $88.85M |
| DFAXDimensional World ex U.S. Core Equity 2 ETF | $78.29M |
Estimated from each fund’s disclosed top holdings × AUM
NVS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NVS’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.